PLRX - PLIANT THERAPEUTICS, INC.

QQQ $ 452.83 $ 6.97 (1.56 %)

DIA $ 399.31 $ 3.70 (0.94 %)

SPY $ 529.09 $ 6.48 (1.24 %)

TLT $ 92.14 $ 1.24 (1.36 %)

GLD $ 220.89 $ 2.80 (1.28 %)

Previous Close

$ 15.36

Open

$ 14.53

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 14.53 - $ 16.48

52 Week Range

$ 11.21 - $ 24.74

Volume

1,269,874

Average Volume

Market Cap

924.38M

Beta (5Y Monthly)

$ 1.03

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-06-2024	03-31-2024	10-Q
2	02-27-2024	12-31-2023	10-K
3	11-09-2023	09-30-2023	10-Q
4	08-09-2023	06-30-2023	10-Q
5	05-09-2023	03-31-2023	10-Q
6	03-09-2023	12-31-2022	10-K
7	11-08-2022	09-30-2022	10-Q
8	08-08-2022	06-30-2022	10-Q
9	05-09-2022	03-31-2022	10-Q
10	02-28-2022	12-31-2021	10-K
11	11-09-2021	09-30-2021	10-Q
12	08-09-2021	06-30-2021	10-Q
13	05-10-2021	03-31-2021	10-Q
14	03-16-2021	12-31-2020	10-K
15	11-10-2020	09-30-2020	10-Q
16	08-11-2020	06-30-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Reiterates Buy on Plia...
05/15/2024 18:00:30

HC Wainwright & Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $36 price target.

pliant-therapeutics-drug-trial-shows-promise-in-reversing-lung-fibrosis-in-patients

Pliant Therapeutics' Drug Trial Shows Prom...
05/14/2024 14:39:54

Phase 2a trial results of Pliant Therapeutics' bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis. Reduced lung coll...

Pliant Therapeutics Announces Positive Top...
05/14/2024 11:34:34

Citigroup Maintains Buy on Pliant Therapeu...
05/07/2024 17:35:34

Citigroup analyst David Lebowitz maintains Pliant Therapeutics (NASDAQ:PLRX) with a Buy and lowers the price target from $45...

these-analysts-revise-their-forecasts-on-pliant-therapeutics-following-q1-earnings

These Analysts Revise Their Forecasts On P...
05/07/2024 15:53:10

RBC Capital Maintains Outperform on Pliant...
05/07/2024 15:14:35

RBC Capital analyst Brian Abrahams maintains Pliant Therapeutics (NASDAQ:PLRX) with a Outperform and lowers the price target...

Oppenheimer Reiterates Outperform on Plian...
05/07/2024 12:37:37

Oppenheimer analyst Jeff Jones reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Outperform and raises the price target fr...

Oppenheimer Maintains Outperform on Pliant...
05/07/2024 12:04:28

Oppenheimer analyst Jeff Jones maintains Pliant Therapeutics (NASDAQ:PLRX) with a Outperform and raises the price target fro...

Needham Reiterates Buy on Pliant Therapeut...
05/07/2024 11:54:21

Needham analyst Joseph Stringer reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $38 price target.

HC Wainwright & Co. Reiterates Buy on Plia...
05/07/2024 10:19:34

HC Wainwright & Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $36 price target.

Pliant Therapeutics Q1 EPS $(0.78) Misses ...
05/06/2024 20:35:45

Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of...

Needham Reiterates Buy on Pliant Therapeut...
04/10/2024 10:45:03

Needham analyst Joseph Stringer reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $38 price target.

Needham Reiterates Buy on Pliant Therapeut...
03/12/2024 16:40:00

Needham analyst Joseph Stringer reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $38 price target.

Pliant Therapeutics Announces Accelerated ...
03/12/2024 11:35:28

Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of ...

RBC Capital Maintains Outperform on Pliant...
03/05/2024 15:32:41

RBC Capital analyst Brian Abrahams maintains Pliant Therapeutics (NASDAQ:PLRX) with a Outperform and raises the price target...

HC Wainwright & Co. Reiterates Buy on Plia...
02/28/2024 17:52:24

HC Wainwright & Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $48 price target.

RBC Capital Maintains Outperform on Pliant...
02/28/2024 15:27:49

RBC Capital analyst Brian Abrahams maintains Pliant Therapeutics (NASDAQ:PLRX) with a Outperform and lowers the price target...

Needham Reiterates Buy on Pliant Therapeut...
02/28/2024 10:28:36

Needham analyst Joseph Stringer reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $38 price target.

Pliant Therapeutics Q4 2023 GAAP EPS $(0.6...
02/27/2024 22:18:35

Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $...

Needham Maintains Buy on Pliant Therapeuti...
02/05/2024 18:54:38

Needham analyst Joseph Stringer maintains Pliant Therapeutics (NASDAQ:PLRX) with a Buy and lowers the price target from $45 ...